CHP Investigates New Locally Acquired Mpox Case Linked to Recent Outbreak at Hutong Restaurant.

CHP investigates confirmed Mpox case epidemiologically linked to "Hutong"

The Centre for Health Protection (CHP) of the Department of Health (DH) said today (June 5) that it is investigating a confirmed locally acquired Mpox (also known as Monkeypox) case epidemiologically linked to the two cases involving in "Hutong" announced on May 25. The CHP has been closely following up on the investigation, including attempting to contact individuals who visited the premises on or after May 1, providing them with health education and continuing to conduct medical surveillance. The CHP urged the public to be vigilant and avoid close physical contact with persons suspected of contracting Mpox. Meanwhile, high-risk target groups are advised to receive Mpox vaccinations.

Case details

—————

The case involves a 52-year-old male who reported to have high-risk contact at a premises called "Hutong" on Shanghai Street, Mong Kok, on May 2 (during the incubation period). He developed a non-pruritic and painless rash over his genital area on May 21, followed by a fever and sore throat on May 25, and a subsequent rash eruption over his upper limbs, chest, and anal region. The CHP made several attempts to contact the patient between the end of May and the beginning of June, but had failed to reach him. The CHP thus sent him a text message. The patient attended the Yau Ma Tei Male Social Hygiene Clinic on June 4 to seek medical treatment and reported relevant high-risk contact history to the healthcare workers. The CHP subsequently arranged for him to receive isolation treatment at the Yan Chai Hospital. The patient is currently in stable condition. His samples tested positive for Monkeypox virus upon laboratory testing by the Public Health Laboratory Services Branch of the CHP.

According to the information provided by the patient, he has not received Mpox vaccination. The CHP is continuing its epidemiological investigations of the case and endeavouring to contact individuals who had high-risk contact with him. The CHP will report the case to the World Health Organization.

Follow-up on the "Hutong" cases in Mong Kok

———————————————

The CHP continues to follow up on the investigation of the cases in "Hutong", and has now successfully contacted around 300 persons who have visited the premises on or after May 1. No other cases have been identified so far. The CHP has provided them with health education and continued to conduct medical surveillance. The CHP again urges anyone who visited the premises on or after May 1 to call the CHP's designated Mpox telephone hotline (2125 2373), so that the CHP can provide health assessments and advice. The hotline operates daily from 9am to 6pm. As investigations are still ongoing, the premises has been closed temporarily starting from May 26.

Furthermore, the CHP will collaborate with Hong Kong AIDS Foundation to launch an outreach Mpox vaccination activity in the next two weeks at the organisation's service centre in Mong Kok. Eligible high-risk groups (especially men who have sex with men) can make an appointment on the organisation's website.

Since 2022, Hong Kong has recorded a total of 88 Mpox cases (71 local cases and 17 imported cases), including the above-mentioned case. All patients were males. Epidemiological investigations revealed that most cases had history of high-risk sexual behaviour, including having sex with strangers or having sex without wearing condoms.

Mpox vaccine

-----------------

Mpox vaccine can prevent infection and severe disease. The DH provides Mpox vaccination services for highrisk groups. The following high-risk target groups are eligible for Mpox vaccinations on a voluntary basis:

• individuals with high-risk sexual practices, e.g. having multiple sexual partners, sex workers, or having a history of sexually transmitted infection within the past 12 months;

• healthcare workersresponsible forcaring forpatients with confirmed Mpox;

• laboratory personnel working with zoonotic pox viruses; and

• animal care personnel with high risk of exposure in caseof Mpox occurrences in animals in Hong Kong.

High-risk target groups can receive Mpox walk-in vaccinations at any of the DH's SocHS (namely Chai Wan SocHS, Wan Chai Male SocHS, Wan Chai Female SocHS, Yau Ma Tei Male SocHS, Yau Ma Tei Female SocHS, Yung Fung Shee SocHS, Fanling SocHS and Tuen Mun SocHS) and the DH's Yau Ma Tei Integrated Treatment Centre.

Meanwhile, the DH's Kowloon Bay Integrated Treatment Centre and the Hospital Authority's Special Medical Clinics at Queen Elizabeth Hospital and Princess Margaret Hospital also provide Mpox vaccination services for their clients.

Mpox is not transmitted through respiratory droplets or aerosols in general, and transmission would not occur through social contact. The CHP reminds the public, especially those at higher risks of exposure, to take precautions and avoid close physical contact with persons or animals suspected of infection. They should seek medical attention as soon as possible if they experience relevant symptoms, including rash, fever, chills, swollen lymph nodes, exhaustion, muscle pain, and severe headaches. They should not engage in activities with others that may involve contact with skin rash or body fluids.

For more details, please visit the CHP's page on Mpox and Mpox Vaccination Programme.

The Centre for Health Protection (CHP), Photo source: reference image

DH convenes 14th Meeting of International Advisory Board on Hong Kong Chinese Materia Medica Standards

The Department of Health (DH) today (July 14) convened the 14th Meeting of the International Advisory Board (IAB) on Hong Kong Chinese Materia Medica Standards (HKCMMS) to review the reference standards for 16 types of Chinese Materia Medica (CMM) commonly used in Hong Kong, and to discuss the future development of the HKCMMS. Over 60 experts from the Chinese Mainland, overseas and Hong Kong attended the meeting.

Since 2002, the DH has been implementing the HKCMMS project in phases to develop standards for commonly used CMM in Hong Kong to ensure their safety and quality.

In his opening remarks, the Director of Health and the Chairperson of the IAB, Dr Ronald Lam, said, "One of the key initiatives of the Government Chinese Medicines Testing Institute (GCMTI) under the DH is the implementation of the HKCMMS. With the publication of the Volume 12 of the HKCMMS, standards for 357 types of CMM have been established so far. They have become widely recognised international reference standards for Chinese medicine testing and certification, thereby promoting the high-quality scientific development of Chinese medicine. In addition, the work of GCMTI is closely aligned with national priorities. The National 15th Five-Year Plan made it clear that we need to 'advance the inheritance and innovation of Chinese medicine' and 'promote the integration of Chinese and Western medicine'. It also calls for us to 'strengthen the conservation and utilisation of Chinese medicine resources', 'improve the quality of Chinese medicine, and build up and strengthen the Chinese medicine industry'. These are exactly the goals that the HKCMMS Project is helping to achieve - by setting rigorous quality standards for CMM and conducting applied research and development on testing methods that underpin the entire industry, establishing the Hong Kong Special Administrative Region as a bridgehead for the global expansion of Chinese Medicine."

Dr Lam emphasised that the success of the HKCMMS project depends on the active collaboration of stakeholders across different sectors. He expressed his sincere appreciation to the four research partners attending the meeting, commending their dedicated contributions to advancing the project's research efforts. They were the National Institutes for Food and Drug Control, the Chinese University of Hong Kong, the Hong Kong Polytechnic University and the China Medical University. He also thanked the Government Laboratory for conducting inter-laboratory verification studies. Dr Lam emphasised that these collaborations are crucial for establishing a rigorous and solid scientific foundation for the HKCMMS and gaining international credibility. The DH is also deeply grateful to the National Medical Products Administration, the National Administration of Traditional Chinese Medicine and the Chinese Pharmacopoeia Commission for their continuous valuable advice and support in developing the HKCMMS. To align with the National 15th Five-Year Plan to advance the inheritance, innovation and high-quality development of Chinese medicine, expand and promote Chinese medicine culture, the DH will continue to steadfastly promote the development of Chinese medicine and better integrate into and serve the overall national development.

The two-day meeting brought together experts from the Chinese Mainland, Australia, Austria, Canada, Germany, Japan, Thailand, the United Kingdom and the United States, as well as representatives from research institutions, the DH and the Government Laboratory of the Hong Kong Special Administrative Region. The 16 types of CMM commonly used in Hong Kong that were discussed at the meeting included Bambusae Caulis in Taenias, Pyrolae Herba, Natrii Sulfas, Dichroae Radix, Dioscoreae Hypoglaucae Rhizoma, Cynanchi Atrati Radix et Rhizoma, Jasmini Flos, Tinosporae Caulis, Inulae Flos, Haematitum, Lasiosphaera seu Calvatia, Vespae Nidus, Dioscoreae Rhizoma, Aconiti Kusnezoffii Folium, Meliae Cortex and Tripterygii Wilfordii Radix.

Previous editions of the HKCMMS can be accessed at the website of the Chinese Medicine Regulatory Office of the DH.

DH convenes 14th Meeting of International Advisory Board on Hong Kong Chinese Materia Medica Standards Source: HKSAR Government Press Releases

DH convenes 14th Meeting of International Advisory Board on Hong Kong Chinese Materia Medica Standards Source: HKSAR Government Press Releases

DH convenes 14th Meeting of International Advisory Board on Hong Kong Chinese Materia Medica Standards Source: HKSAR Government Press Releases